NDA 021286 · Cosette
Benicar
Olmesartan Medoxomil · Oral
NovelLast checked: Nov 20, 2026Latest source record: Oct 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Apr 25, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
141
56 Phase 3, 4 recruiting
FAERS reports
36,093
23,598 serious, 1,635 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benicar as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ). WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Benicar as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).
What it is approved for
From the label in effect Sep 23, 2025.
Benicar is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at...
Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 4, 2010 Supplement 18 · Efficacy · priority review LabelLetter
- Apr 25, 2002 Original approval · Type 1 - New Molecular Entity NovelLetterPediatric Medical ReviewPediatric Clinical Pharmacology Review
3 products under this application
- BENICAR · OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
- BENICAR · OLMESARTAN MEDOXOMIL 5MG · TABLET, ORAL · Prescription · TE AB
- BENICAR · OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Olmesartan Medoxomil" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Polypills Approach for Multiple Cardiovascular Risk FactorsPivotal-lookingRecruiting
China Medical University, ChinaAcademic, hospital or other
NCT07679828 · 8,252 participants (planned) · Start Jul 11, 2026 · Primary completion Dec 31, 2029
Drug: Fixed-Dose Combination Strategy · For: Hypertension; Dyslipidemia; Diabetes
Sites: Zhengzhou, China; Chifeng, China; Tongliao, China · 15 sites in all
- Strategy of Blood Pressure Intervention in the Elderly Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT03015311 · 8,000 participants (planned) · Start Jan 15, 2017 · Primary completion Dec 31, 2020
Drug: Intensive BP control; Standard BP control · For: Primary Hypertension
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 42 sites in all
- Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)Pivotal-lookingCompleted
COLM Study Research OrganizationAcademic, hospital or other
NCT00454662 · 5,141 participants · Start Apr 2007 · Primary completion Sep 2011
Drug: olmesartan medoxomil / amlodipine or azelnidipine; olmesartan medoxomil / low dose thiazide type drug · For: Hypertension; Cardiovascular Disease; Diabetes
Sites: Kamiyacho Mount Bld.14F, 4-3-20 Toranomon Minato-ku, Japan
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
- Olmesartan Medoxomil in Diabetes MellitusPivotal-lookingCompleted
Sankyo Pharma GmbhIndustry
NCT00185159 · 4,449 participants · Start Oct 2004 · Primary completion Jul 2009
Drug: Olmesartan medoxomil; Placebo Tablets · For: Diabetes Mellitus, Type 2; Cardiovascular Disease; Kidney Disease
Sites: Darmstadt, Germany
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- sprue-like enteropathy3,497
- diarrhoea2,512
- weight decreased2,231
- dizziness2,127
- gastrooesophageal reflux disease2,079
- nausea2,059
- acute kidney injury2,028
- drug ineffective1,997
- fatigue1,702
- headache1,428
- haemorrhoids1,369
- dyspnoea1,362
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 486 |
| 2005 | 567 |
| 2006 | 572 |
| 2007 | 777 |
| 2008 | 1,069 |
| 2009 | 1,285 |
| 2010 | 1,815 |
| 2011 | 1,741 |
| 2012 | 1,930 |
| 2013 | 1,205 |
| 2014 | 1,455 |
| 2015 | 2,878 |
| 2016 | 2,914 |
| 2017 | 3,142 |
| 2018 | 3,211 |
| 2019 | 2,113 |
| 2020 | 1,373 |
| 2021 | 1,203 |
| 2022 | 1,537 |
| 2023 | 1,436 |
| 2024 | 1,168 |
| 2025 | 1,210 |
| 2026 | 1,006 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Benicar (Olmesartan Medoxomil)
2024 spending
$14.0M
Beneficiaries
4,009
19,325 claims
Per beneficiary
$3,493
$11.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,401,793 |
| 2021 | $18,176,654 |
| 2022 | $16,185,464 |
| 2023 | $15,710,812 |
| 2024 | $14,002,739 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Telemonitoring of blood pressure self measurement in the OLMETEL study.
Mengden T, Ewald S, Kaufmann S, et al. · Blood Press Monit 2004 · Clinical Trial, Consensus Statement
- Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients.
Redon J, Weber MA, Reimitz PE, et al. · J Clin Hypertens (Greenwich) 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Fliser D, Buchholz K, Haller H · Circulation 2004 · Clinical Trial, Clinical Trial, Phase III
- Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.
Baguet JP, Legallicier B, Auquier P, et al. · Clin Drug Investig 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual-Combination Therapy.
Rump LC, Ammentorp B, Laeis P, et al. · J Clin Hypertens (Greenwich) 2016 · Clinical Trial, Phase III, Multicenter Study
- Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.
Püchler K, Laeis P, Stumpe KO · J Hypertens Suppl 2001 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.